1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1007/s12035-017-0707-z" target="_blank" rel="noreferrer noopener">http://doi.org/10.1007/s12035-017-0707-z</a>
Pages
5167–5176
Issue
6
Volume
55
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Glycoprotein NMB: an Emerging Role in Neurodegenerative Disease.
Publisher
An entity responsible for making the resource available
Molecular neurobiology
Date
A point or period of time associated with an event in the lifecycle of the resource
2018
2018-06
Subject
The topic of the resource
Animals; GPNMB; Humans; Immune System/metabolism; Membrane Glycoproteins/chemistry/*metabolism; Nerve Degeneration/pathology; Neurodegeneration; Neurodegenerative Diseases/*metabolism/therapy; Neuroinflammation; Neuroprotection
Creator
An entity primarily responsible for making the resource
Budge Kevin M; Neal Matthew L; Richardson Jason R; Safadi Fayez F
Description
An account of the resource
Neurodegeneration is characterized by severe neuronal loss leading to the cognitive and physical impairments that define various neurodegenerative diseases. Neuroinflammation is one hallmark of neurodegenerative diseases and can ultimately contribute to disease progression. Increased inflammatory cytokines, such as interleukin-6 (IL-6), interleukin-1beta (IL-1 beta), and tumor necrosis factor-alpha (TNF-alpha) are associated with Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS), and multiple sclerosis (MS). Unfortunately, current therapeutic options lack ability to stop or effectively slow progression of these diseases and are primarily aimed at alleviating symptoms. Thus, it is crucial to discover novel treatment candidates for neurodegenerative diseases. Glycoprotein nonmetastatic melanoma protein B (GPNMB) is a type-I transmembrane glycoprotein first identified in a melanoma cell line. GPNMB augments bone mineral deposition by stimulating osteoblast differentiation. Aside from its anabolic function in the bone, emerging evidence suggests that GPNMB has anti-inflammatory and reparative functions. GPNMB has also been demonstrated to be neuroprotective in an animal model of ALS, cerebral ischemia, and other disease models. Given these discoveries, GPNMB should be investigated as a potential therapeutic option for multiple neurodegenerative diseases.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1007/s12035-017-0707-z" target="_blank" rel="noreferrer noopener">10.1007/s12035-017-0707-z</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
2018
Animals
Budge Kevin M
Department of Anatomy & Neurobiology
Department of Pharmaceutical Sciences
GPNMB
Humans
Immune System/metabolism
Membrane Glycoproteins/chemistry/*metabolism
Molecular neurobiology
Neal Matthew L
NEOMED College of Medicine
NEOMED College of Pharmacy
Nerve Degeneration/pathology
Neurodegeneration
Neurodegenerative Diseases/*metabolism/therapy
Neuroinflammation
Neuroprotection
Richardson Jason R
Safadi Fayez F